Mỹ cho phép dùng thuốc Remdesivir trong điều trị bệnh COVID-19

Thông báo của Cơ quan Quản lý Thực phẩm và Dược phẩm Mỹ (FDA) ngày 22/10 cho biết, cơ quan này đã cấp phép sử dụng thuốc Remdesivir (do công ty Gilead Sciences phát triển) trong điều trị bệnh viêm đường hô hấp COVID-19.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Hy vọng mới trong điều trị ung thư tuyến tụy

Hy vọng mới trong điều trị ung thư tuyến tụy

Thế giới
(Baothanhhoa.vn) - Một loại thuốc thử nghiệm có tên Daraxonrasib đang mở ra hy vọng mới trong điều trị ung thư tuyến tụy, sau khi kết quả nghiên cứu công bố trên tạp chí y khoa New England Journal of Medicine cho thấy thuốc có thể giúp kéo dài gấp đôi thời gian sống...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh